-Advertisement-
-Advertisement-
Alagille Syndrome
New treatment shows promise for patients with primary biliary cholangitis
Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has demonstrated significant efficacy in treating primary biliary cholangitis (PBC), according to results of a Phase 3 trial. The trial showed that seladelpar resulted in a higher percentage of patients achieving a biochemical response and normalization of alkaline phosphatase levels compared to the...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved